Background. Metabolic syndrome (MS) with hyperandrogenism comorbidity in women is considered a common concept; however, the contribution of the neuroendocrine regulation system indicators to this in reproductive age remains unclear.The aim. To analyze the activity of neuroendocrine regulation system in women of reproductive age of different ethnic groups with metabolic syndrome associated with hyperandrogenism.Materials and methods. The groups of women with MS of Russian (n = 209) and Buryat (n = 84) ethnic groups and a group of women with MS and polycystic ovary syndrome (PCOS) of Russian (n = 23) and Buryat (n = 10) ethnic groups were formed.Results. In women of reproductive age of the Russian ethnic group with MS and PCOS the study noted higher levels of anti-Müllerian hormone (AMH) (p = 0.030), testosterone (Ts) (p = 0.026), free androgen index (FAI) (p < 0.0001), dehydroepiandrosterone sulfate (DHEA-S) (p < 0.0001), and reduced levels of sex hormone-binding globulin (SHBG) (p < 0.0001) in relation to the control; in relation to the group with MS, we discovered increased values of AMH (p < 0.001), Ts (p = 0.030), FAI (p < 0.001), DHEA-S (p < 0.0001), and decreased values of SHBG (p = 0.001). In women of the Buryat ethnic group with MS and PCOS the study recorded increased values of AMH (p = 0.045), Ts (p = 0.002), FAI (p < 0.0001), DHEA-S (p = 0.033), decreased SHBG (p = 0.016) and 17-OH-progesterone (p = 0.027) levels in comparison with the control; in comparison with the group with MS we noted a higher level of DHEA-S (p = 0.006) and a decreased level of SHBG (p = 0.028).Conclusion. Women with metabolic syndrome associated with hyperandrogenism showed more intense changes in the neuroendocrine regulation system relative to control values regardless of ethnicity. In Russian women, the combined syndrome (MS with PCOS) was accompanied by a greater number of hormonal changes compared to the monosyndrome (MS) than in Buryat women. The data obtained indicate the need to assess and control the content of these metabolites in women with MS and PCOS, taking into account ethnicity.
